Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

<p>– The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit – Trial demonstrated the long-term safety of TransCon hGH in patients treated up to 6 years COPENHAGEN, Denmark, Sept. 23, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/ascendis-pharma-presents-results-from-long-term-enlighten-trial-of-transcon-hgh-in-pediatric-growth-hormone-deficiency/">Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>